*Inferior in the primary indication of lowering trigs
*No big pharma support
*Generic Lovaza from 2015
*Not a known product, long term consequences of getting 4g of EPA per day and no DHA not established
*Going against all known recommendations of increasing DHA intake (incl. the doc's own)
*Massive competition from cheaper supplements freeriding on Amarin's desperate marketing of Vascepa
Reasons AMARIN will fail:
*Se all of the above
*COGS (cost of buying the extremely expensive API for Vascepa)
*SG&A (enormous costs of building sales, marketing, support and legal from scratch)
*After all COGS and SG&A and dramatically lower end user prices from 2015, margins will be NEGATIVE (only losses, month after month, quarter after quarter and so on).
*No further access to either equity or debt funding
Sentiment: Strong Sell
So, if YOU have high tryglicerides and a your family has heart history problems, which would you take ? U are an idiot !!! Take Lovaza and die SHORTY !!!
Tons of patients worldwide are taking Lovaza/Omacor/Lotriga and they are doing great..
It's probably the most tested and safe drug in the world (used in thousands of clinical trials over two decades).
96% EPA/Vascepa on the other hand is left for dead by BP worldwide, even in Japan!
how many shares you short?
So anyone not fanatically bullish on AMRN must be short, is that what you are trying to say?